We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Olema Pharmaceuticals Inc (OLMA) USD0.0001

Sell:$2.19 Buy:$2.21 Change: $0.01 (0.45%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.01 (0.45%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.01 (0.45%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. It is designed based on a structural understanding of the ER. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including a breast cancer brain metastasis model. It is in the Phase I/ IIclinical trial, and in Phase I combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Contact details

512 2Nd Street, 4Th Floor, Suite 250
United States
+1 (415) 7428265

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$87.16 million
Shares in issue:
40.35 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Sean Bohen
    President, Chief Executive Officer, Director
  • Peter Kushner
    Co-Founder, Non-Executive Director, Senior Research Fellow
  • Shane Kovacs
    Chief Financial Officer, Chief Operating Officer
  • John Moriarty
    Executive Vice President, Company Secretary, Chief Legal Officer
  • Kinney Horn
    Chief Business Officer
  • David Myles
    Chief Development Officer
  • Naseem Zojwalla
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.